CANSINO BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.28 CNY | -3.16% |
|
+4.31% | -28.50% |
| Apr. 29 | CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's enterprise value to sales, at 5.22 times its current sales, is high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -28.50% | 1.19B | - | ||
| -2.61% | 89.08B | A- | ||
| +3.55% | 40.9B | A- | ||
| -14.40% | 32.25B | B- | ||
| +55.89% | 25.14B | A | ||
| -15.96% | 15.39B | C | ||
| -15.50% | 11.91B | B- | ||
| -41.29% | 11.89B | B | ||
| -11.75% | 11.64B | D+ | ||
| +7.87% | 9.03B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6185 Stock
- 688185 Stock
- Ratings CanSino Biologics Inc.